CN117106622A - Lactobacillus plantarum and application of composition thereof in preparation of medicines for treating internal hemorrhoids - Google Patents

Lactobacillus plantarum and application of composition thereof in preparation of medicines for treating internal hemorrhoids Download PDF

Info

Publication number
CN117106622A
CN117106622A CN202310745600.XA CN202310745600A CN117106622A CN 117106622 A CN117106622 A CN 117106622A CN 202310745600 A CN202310745600 A CN 202310745600A CN 117106622 A CN117106622 A CN 117106622A
Authority
CN
China
Prior art keywords
lactobacillus plantarum
preparation
viable bacteria
bacteria preparation
lactobacillus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202310745600.XA
Other languages
Chinese (zh)
Other versions
CN117106622B (en
Inventor
陈廷涛
林枫翔
刘辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harbin Meihua Biotechnology Co ltd
Original Assignee
Harbin Meihua Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harbin Meihua Biotechnology Co ltd filed Critical Harbin Meihua Biotechnology Co ltd
Priority to CN202310745600.XA priority Critical patent/CN117106622B/en
Publication of CN117106622A publication Critical patent/CN117106622A/en
Application granted granted Critical
Publication of CN117106622B publication Critical patent/CN117106622B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/25—Lactobacillus plantarum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention belongs to the technical field of microorganism application, and in particular relates to application of a live bacteria preparation in preparation of a medicine for treating internal hemorrhoids. The viable bacteria preparation disclosed by the invention can effectively improve the intestinal flora diversity after operation, and improves the relative abundance of the Firmicutes at the gate level; the relative abundance of bifidobacteria (bifidobacteria), megamonas (Megamonas) and Lactobacillus (Lactobacillus) is increased at the genus level; improves the improvement rate of the internal hemorrhoid endoscopic hardening treatment, and has higher clinical safety.

Description

Lactobacillus plantarum and application of composition thereof in preparation of medicines for treating internal hemorrhoids
Technical Field
The invention belongs to the technical field of microorganism application, and in particular relates to application of a live bacteria preparation in preparation of a medicine for treating internal hemorrhoids.
Background
Internal hemorrhoids are the most common type of hemorrhoids, well developed in adults over 50 years of age, and are mainly characterized clinically by bleeding and prolapse. The occurrence of internal hemorrhoid symptoms is usually caused by drinking, spicy diet and abnormal intestinal habit (especially constipation). The costs associated with the onset of long-term symptoms and with the treatment of internal hemorrhoids, lead to serious problems in the daily life of the patient and may increase the risk of complications.
Endoscopic sclerotherapy has been an improvement over 100 years, and is now widely used in minimally invasive therapy for internal hemorrhoids, providing a simple and effective alternative to traditional hemorrhoidectomy. The principle of endoscopic sclerotherapy is to induce aseptic inflammation and fibrosis by endoscopically injecting sclerosant to reduce the volume of internal hemorrhoids. Although endoscopic sclerotherapy has good clinical efficacy, postoperative complications including pain, bleeding, infection, and recurrence are still common, and it is reported that about 40% of patients still have varying degrees of bleeding within one month after surgery. In addition, endoscopic surgery can cause post-operative intestinal dysfunction, and intestinal preparation prior to endoscopic surgery can also cause significant disturbance of the intestinal flora, with recovery times exceeding two weeks, possibly exacerbating symptoms of internal hemorrhoids. The occurrence of postoperative symptoms severely reduces the quality of life of the patient, and methods for reducing the occurrence rate of such symptoms and regulating the dysbacteriosis are sought to further improve the efficacy of endoscopic sclerotherapy.
Probiotics are defined as active microorganisms that benefit a host upon ingestion in sufficient amounts. Lactobacillus plantarum (original name Lactobacillus plantarum) is an important probiotic genus, has excellent acid resistance and intestinal mucosa adhesion, and can play roles by producing antibacterial metabolites, changing intestinal microecological environment, enhancing immune system and other mechanisms. Lactobacillus plantarum has been shown to significantly improve intestinal function, reduce intestinal transit time, increase the number of spontaneous bowel movements (SBM, spontaneous bowel movement), and improve stool consistency. In addition, both in vivo and in vitro studies have shown that lactobacillus plantarum can effectively reduce intestinal inflammation and improve the diversity and richness of intestinal flora. Our previous studies have also demonstrated that oral probiotics are effective in alleviating gastrointestinal symptoms following intestinal surgery and promoting recovery of intestinal flora. Based on this, the use of lactobacillus plantarum after endoscopic sclerotherapy may have an adjuvant therapeutic effect, but lacks clinical relevant research reports.
The auxiliary materials are basic materials and important components of the pharmaceutical preparation, and play a vital role in the preparation technology, the pharmaceutical dosage form and the production of medicines. Therefore, the preparation not only endows the medicine with a certain dosage form, but also has great influence on the administration route and the product quality, including the acting speed, the absorption speed, the bioavailability, the toxic and side effects and the like after the medicine is taken. In pharmaceutical dosage forms, the pharmaceutical activity and physical and chemical stability are the main part, determining the overall efficacy of the formulation. The auxiliary materials are used for realizing the research and development purposes of the preparation technology and ensuring that the medicine is released at a certain position in vivo at a certain speed and time. Therefore, the preparation consisting of the proper auxiliary materials plays a vital role in the practical application and the curative effect of the medicine.
Based on the analysis, the lactobacillus plantarum combined adjuvant is hopeful to be developed for auxiliary treatment after an endoscopic sclerosis treatment operation, including the influence on postoperative internal hemorrhoid symptoms and intestinal functions, and the potential treatment mechanism is analyzed through high-throughput sequencing of postoperative intestinal flora. The study aims at filling the blank of the prior knowledge and provides valuable insight for using the probiotic preparation as an auxiliary treatment for internal hemorrhoid treatment.
Disclosure of Invention
The terms in the present invention:
the lactobacillus plantarum composition is a living bacteria preparation.
"Lactobacillus plantarum" is equivalent to "Lactobacillus plantarum"
The "Shannon index" evaluates the abundance and uniformity of species composition in a sample. A larger value indicates a richer species of the environment and a more uniform distribution of each species.
The "Simpson index" randomly takes two OTUs from one sample data, which are probabilities of belonging to different species. The greater this probability means the higher the species diversity of the sample, and vice versa. The index allows assessment of the status and role of dominant species in the community.
"Chao1 index" estimates an index of the number of OTUs contained in a sample, with a larger number representing more species contained in the sample.
"OTU", operational taxonomic units, is one of the most common terms in microbiological studies, and in order to facilitate the study of species composition diversity information of samples, effective sequences of samples need to be clustered, clean tags are clustered into OTUs under default given similarity (default 97%), so as to obtain sequences of each cluster, and a number (OTU ID) is randomly assigned to each sequence. One OTU can generally be considered to correspond to one species.
The "PCoA analysis" (Principal Coordinate Analysis ) is to find principal coordinates based on a distance matrix, and extract and visualize the most important elements and structures from complex data by dimension-reducing multi-dimensional data.
The "Golight classification" method, proposed by Golight in 1980, classifies internal hemorrhoids into classes I-IV according to the degree of prolapse of hemorrhoids, and suggests outpatient treatment of patients of classes I and II, with hemorrhoidectomy of classes III and IV.
The "n-HDSS score" is a modified version of the study based on HDSS score, including five symptoms (bleeding, pain, itching, staining and prolapse), with a score of 0-3 per item (0=less than once per month, 1=less than once per week, 2=1-6 days per week, 3=daily or always).
The "SHS score" consists of four questions (severity, impact on life, attention, and well-being), each with a score of 1-7,1 = asymptomatic, 7 = severe symptoms.
"SBM" (spontaneous bowel movement, spontaneous defecation) is defined as the behavior of defecation without laxatives. "SBMs" are defined as the number of spontaneous bowel movements.
"HLS" (hard or lumpy stools) is defined as a spontaneous bowel movement type with type 0-1 bowel movement (Bristol bowel movement scale).
The "ITT Analysis" (Analysis of intent) is the result of a clinical trial that contains all of the randomized group of patient follow-up data.
In order to solve the problems, the invention discloses a viable bacteria preparation which can effectively improve the intestinal flora diversity after operation, and the relative abundance of the Firmicutes is improved at the gate level; the relative abundance of bifidobacteria (bifidobacteria), megamonas (Megamonas) and Lactobacillus (Lactobacillus) is increased at the genus level; improving the improvement rate of the internal hemorrhoid endoscopic hardening treatment.
In one aspect, the invention provides a live bacteria preparation, which comprises lactobacillus plantarum MH-301 and auxiliary materials;
the preservation number of the lactobacillus plantarum MH-301 is CGMCC NO.18618;
the auxiliary materials include, but are not limited to: resistant dextrins, fructooligosaccharides, stachyose, xylitol and inulin.
In particular, the viable count of the lactobacillus plantarum MH-301 is more than or equal to 1 multiplied by 10 9 cfu/g。
Specifically, the mass ratio of the resistant dextrin, fructo-oligosaccharide, stachyose, xylitol and inulin is 8-14:5-12:8-10:4-6:4-8.
Preferably, the mass ratio of the resistant dextrin, fructo-oligosaccharide, stachyose, xylitol and inulin is 14:5:10:4:8.
preferably, the mass ratio of the resistant dextrin, fructo-oligosaccharide, stachyose, xylitol and inulin is 4:6:4:3:2.
specifically, the mass ratio of the lactobacillus plantarum MH-301 to the auxiliary materials is 5-8:38-41.
Preferably, the mass ratio of the lactobacillus plantarum MH-301 to the auxiliary materials is 5:41.
on the other hand, the invention also provides application of the live bacteria preparation in preparing medicines for treating internal hemorrhoids.
In particular, the viable bacteria preparation is used for improving intestinal microbiota.
Further specifically, the viable bacteria preparation is used for improving intestinal flora diversity.
In yet another aspect, the invention provides the use of the aforementioned live bacterial formulation in food or health care products.
In particular, the health care product is used for improving intestinal microbiota.
Further specifically, the health care product is used for improving intestinal flora diversity.
The invention has the technical effects that:
(1) Improving the rate of the hardening treatment of the internal hemorrhoid endoscope;
(2) Shortens the first spontaneous defecation (SBM) time of patients and reduces the number proportion of patients with HLS more than or equal to 25% SBMs;
(3) The use rate and complications of laxatives in the course of disease are reduced;
(4) At the gate level, the relative abundance of Firmicutes (Firmicutes) is increased;
(5) The relative abundance of bifidobacteria (bifidobacteria), megamonas (Megamonas) and Lactobacillus (Lactobacillus) is increased at the genus level;
(6) Has higher clinical safety.
Drawings
FIG. 1 is a bar graph of improvement rate of endoscopic sclerosis treatment of internal hemorrhoids.
Detailed Description
The present invention will be described in further detail with reference to the following examples, which are not intended to limit the present invention, but are merely illustrative of the present invention. The experimental methods used in the following examples are not specifically described, but the experimental methods in which specific conditions are not specified in the examples are generally carried out under conventional conditions, and the materials, reagents, etc. used in the following examples are commercially available unless otherwise specified.
Lactobacillus plantarum MH-301, accession number: CGMCC No.18618.
Maltodextrin, rui Chengkang medicine technology (Shanxi Co., ltd.), product number: pharmaceutical grade maltodextrin.
Resistant dextrin, shenzhen Lefu Biotechnology Co., ltd., product number: ZCJ0704.
Fructooligosaccharides, marKamick technologies Co., ltd., product number: 308066-66-2.
Stachyose, shanghai Kogyo commercial Co., ltd., product number: FK3198.
Xylitol, xian jin Xiang pharmaceutical excipients Co., ltd., product number: 180-9270-5451.
Inulin, chongqing Rui Yao Biotechnology Co., ltd., product number: 9005-80-5.
Preparation of basic experiment lactobacillus plantarum MH-301 bacterial powder
The lactobacillus plantarum MH-301 powder is prepared by a conventional method, and the method comprises the following steps:
taking seed freezing tube of Lactobacillus plantarum MH-301, activating in MRS culture medium at 37deg.C, continuously activating for three generations, inoculating activated Lactobacillus plantarum MH-301 into fermentation tank containing MRS culture medium, fermenting, centrifuging with centrifuge after fermentation, collecting thallus, lyophilizing in lyophilizing machine, pulverizing to obtain bacterial powder with bacterial count of more than or equal to 1×10 10 cfu/g。
Example 1
The present example provides a viable bacteria preparation, the formulation is shown in Table 1:
TABLE 1
Component (g) Lactobacillus plantarum MH-301 powder Resistant dextrins Fructooligosaccharides Stachyose Xylitol Inulin
Dosage of 0.5 1.4 0.5 1 0.4 0.8
Example 2
This example provides a viable bacteria formulation, the formulation is shown in table 2:
TABLE 2
Component (g) Lactobacillus plantarum MH-301 powder Resistant dextrins Fructooligosaccharides Stachyose Xylitol Inulin
Dosage of 0.8 0.8 1.2 0.8 0.6 0.4
Comparative example
The formulation of the viable bacteria preparation of the comparative example is shown in Table 3
TABLE 3 Table 3
Component (g) Lactobacillus plantarum MH-301 powder Resistant dextrins Fructooligosaccharides Stachyose Xylitol Inulin
Comparative example 1 0.5 1.4 0.5 1.4 0 0.8
Comparative example 2 0.5 1.4 0.5 0 1.4 0.8
Comparative example 3 0.5 1.4 0 1 0.4 1.3
Comparative example 4 0.5 1.4 1.3 1 0.4 0
Example 2 clinical trial
2.1 patient data information and grouping
2.1.1 subject enrollment criteria
Age >18 years old; patients who are classified as class I-III parallel endoscopic sclerotherapy according to golghter's. The invention is approved by the ethical committee of hospitals, all patients agree informed, and good life work and rest time and eating habits can be maintained during the trial period.
A total of 360 patients assessed as eligible for this study were enrolled from 2021-05-01 to 2022-10-31, with 338 (16 disqualified, 6 rejected participation) eventually randomized and enrolled 42 per ITT analysis experimental group, control group (C) 44.
The 8 groups of patients had no significant differences in age, sex, BMI, golight's classification. There was no statistical difference between the pre-operative n-HDSS score and the SHS score of the patient. The baseline data for the patients in the group are shown in tables 4 and 5.
TABLE 4 Table 4
TABLE 5
2.1.2 groupings and experimental designs were as follows:
the placebo for the control group was maltodextrin. The positive medicine is mailing tablet, each tablet contains 150mg of horse chestnut extract, and the manufacturer: the German Gift Dada pharmaceutical factory; approval document: the national medicine standard character size ZJ20140002. The specific usage amounts are shown in Table 6.
TABLE 6
Group of Numbering device Drug name Dosage of usage
Control group (n=44) A Maltodextrin 1 g/time, 3 times daily
Positive drug group (n=42) B Mailing tablet 2 tablets/time, 2 times daily
Example 1 (n=42) C Example 1 1 g/time, 3 times daily
Example 2 (n=42) D Example 2 1 g/time, 3 times daily
Comparative example 1 (n=42) E Comparative example 1 1 g/time, 3 times daily
Comparative example 2 (n=42) F Comparative example 2 1 g/time, 3 times daily
Comparative example 3 (n=42) G Comparative example 3 1 g/time, 3 times daily
Comparative example 4 (n=42) H Comparative example 4 1 g/time, 3 times daily
Each group needs to complete the taking follow-up for 4 weeks, and provides a fecal sample (S) for high-throughput sequencing and metabonomics analysis (after taking for 1 week), the collected fecal sample is placed in a sterile plastic container and stored to a laboratory at 4 ℃; the samples were kept for less than 8 hours before reaching the laboratory and the faeces were stored in a-80 refrigerator immediately after reaching until DNA was extracted.
2.1.3 measurement index
(1) Follow-up index: (1) 4 weeks post-operative good turnover, n-HDSS score, SHS score; (2) intestinal function 4 weeks after surgery: first time SBM time, SBMs, HLS is more than or equal to 25% SBMs, and laxative use condition; (3) postoperative complications and safety indexes.
(2) High throughput and metabonomic analysis of faeces: and (5) analyzing the microbial diversity, the abundance, the species composition classification and the like of the feces.
2.2 analysis of results
2.2.1 evaluation of postoperative symptom improvement
The experimental results are shown in Table 7, and the improvement rate of the endoscopic sclerosis treatment of internal hemorrhoids is higher in the examples 1-2 compared with the control group, and the use rate and the complications of the cathartic are lower than those of the control group; examples 1-2 showed slightly lower improvement than the positive group, but the laxative use rate and complications were much lower than the positive group; examples 1-2 have a shorter time to first SBM (spontaneous bowel movement) and a lower proportion of patients with HLS (hard or lumpy stools).gtoreq.25% SBMs than the control and positive groups. The results show that the examples 1-2 can effectively improve the adverse symptoms of internal hemorrhoids after operation, the improvement rate reaches more than 88 percent, and the patients with HLS more than or equal to 25 percent of SBMs have low number proportion, although the patients have slightly lower time for first SBM than positive drugs; and the usage rate and complications of the cathartic are lower than half of those of the positive medicine, so that the safety is higher.
As can be seen from the comparison of examples 1-2 and examples 1-4, the improvement rates of examples 1-2, the time to first SBM, and the proportion of patients with HLS.gtoreq.25% SBMs were all superior to those of comparative examples 1-4; but the laxative use rate and complications were not significantly different. As is clear from comparative examples 1-2 and comparative examples 3-4, stachyose and xylitol in the auxiliary materials have a larger influence on the effect of the live bacteria preparation; fructooligosaccharides and inulin also have a certain influence, but relatively small influence. The results show that the addition of auxiliary materials and the addition amount of the auxiliary materials can influence the drug effect to a certain extent, the bioavailability of the drug, the acting time or the acting time.
TABLE 7
2.2.2 postoperative intestinal flora diversity analysis
Examples 1-2 were high in Shannon and Simpson indices of α -diversity compared to the control group, while there was no significant difference in Chao1 and good coverage indices. In terms of β -diversity, principal coordinate analysis (PCoA) showed that examples 1-2 had significant microbiota composition clusters, indicating that examples 1-2 had significant impact on intestinal microbiota. At the genus level, LEfSe (LDA effect size) analysis showed that the relative abundance of Bifidobacterium (Bifidobacterium), megamonas (Megamonas) and Lactobacillus (Lactobacillus) of examples 1-2 was higher. The relative abundance of Bifidobacterium and Lactobacillus in the positive drug group was decreased compared to the control group. Examples 1-2 were not significantly different from comparative examples 1-4.
Species composition analysis at the gate level showed that examples 1-2 had higher relative abundance of Firmicutes compared to the control group, while bacteroides (bacterioides) did not differ significantly. At the genus level, the groups of examples 1-2 also had higher relative abundance of Bifidobacterium, megamonas and Lactobacillus, but there was no significant difference between the two groups among Prevotella, dorea and Ruminococcus. At the portal level, firmics and Bactroides were both reduced in the positive group compared to the control group; at the genus level, the relative abundance of Bifidobacterium and Lactobacillus was also reduced compared to the control. Examples 1-2 were not significantly different from comparative examples 1-4.
The results show that the viable bacteria preparations of the examples and the comparative examples improve the diversity of intestinal bacteria at a certain level; the positive medicine group reduces the diversity of intestinal bacteria to a certain extent, which can be the reason of side effects of medicines such as stomachache, gastrectasia, diarrhea, vomiting, dyspepsia and the like.
2.2.3 Security analysis
There were no significant differences in the incidence of adverse reactions during follow-up in the 8 groups of patients, and 2 cases of gastroesophageal reflux disease in the positive drug group; example 1 has 1 insomnia and 1 vertigo; comparative example 2 had 1 pneumonia and 1 insomnia; the control group had 2 cases of pneumonia, 1 case of gastroesophageal reflux disease and 1 case of vertigo, all symptoms were grade 1 (mild). It was initially thought that these symptoms might not be associated with the use of live bacterial preparations, and that no serious complications or deaths occurred during follow-up.

Claims (10)

1. The live bacteria preparation is characterized by comprising lactobacillus plantarum MH-301 and auxiliary materials; the preservation number of the lactobacillus plantarum MH-301 is CGMCC NO.18618; the auxiliary materials comprise resistant dextrin, fructo-oligosaccharide, stachyose, xylitol and inulin.
2. The viable bacteria preparation of claim 1, wherein the viable bacteria number of Lactobacillus plantarum MH-301 is not less than 1×10 9 cfu/g。
3. The viable bacteria preparation according to claim 1, wherein the mass ratio of the resistant dextrin, fructo-oligosaccharide, stachyose, xylitol and inulin is 8-14:5-12:8-10:4-6:4-8.
4. The viable bacteria preparation according to claim 3, wherein the mass ratio of the resistant dextrin, fructo-oligosaccharide, stachyose, xylitol and inulin is 14:5:10:4:8.
5. the viable bacteria preparation according to claim 3, wherein the mass ratio of the resistant dextrin, fructo-oligosaccharide, stachyose, xylitol and inulin is 4:6:4:3:2.
6. the viable bacteria preparation of claim 1, wherein the mass ratio of lactobacillus plantarum MH-301 to auxiliary materials is 5-8:38-41.
7. The viable bacteria preparation of claim 6, wherein the mass ratio of lactobacillus plantarum MH-301 to auxiliary materials is 5:41.
8. use of a live bacterial formulation according to any one of claims 1 to 7 for the preparation of a medicament for the treatment of internal hemorrhoids.
9. The use according to claim 8, wherein the viable bacteria preparation is for improving intestinal microbiota.
10. Use of the viable bacteria preparation of any one of claims 1-7 in food or health products.
CN202310745600.XA 2023-06-21 2023-06-21 Lactobacillus plantarum and application of composition thereof in preparation of medicines for treating internal hemorrhoids Active CN117106622B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310745600.XA CN117106622B (en) 2023-06-21 2023-06-21 Lactobacillus plantarum and application of composition thereof in preparation of medicines for treating internal hemorrhoids

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310745600.XA CN117106622B (en) 2023-06-21 2023-06-21 Lactobacillus plantarum and application of composition thereof in preparation of medicines for treating internal hemorrhoids

Publications (2)

Publication Number Publication Date
CN117106622A true CN117106622A (en) 2023-11-24
CN117106622B CN117106622B (en) 2024-05-10

Family

ID=88806264

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310745600.XA Active CN117106622B (en) 2023-06-21 2023-06-21 Lactobacillus plantarum and application of composition thereof in preparation of medicines for treating internal hemorrhoids

Country Status (1)

Country Link
CN (1) CN117106622B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2532062A1 (en) * 2005-01-14 2006-07-14 Nutrinor Cooperative Agro-Alimentaire Du Saguenay Lac St-Jean Food composition for maintaining and restoring digestive functions
CN107205634A (en) * 2015-01-22 2017-09-26 博尔斯研究生产股份公司 Proctoscope
CN111035661A (en) * 2018-10-15 2020-04-21 深圳市华大农业应用研究院 Application of lactobacillus plantarum

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2532062A1 (en) * 2005-01-14 2006-07-14 Nutrinor Cooperative Agro-Alimentaire Du Saguenay Lac St-Jean Food composition for maintaining and restoring digestive functions
CN107205634A (en) * 2015-01-22 2017-09-26 博尔斯研究生产股份公司 Proctoscope
CN111035661A (en) * 2018-10-15 2020-04-21 深圳市华大农业应用研究院 Application of lactobacillus plantarum

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
王丽媛;谢咏梅;汪志凌;高珊;: "益生菌调节轮状病毒肠炎患儿肠道菌群的动态变化", 实用儿科临床杂志, no. 07, 5 April 2011 (2011-04-05) *
门月华;闫慧敏;赵慧娟;郭独一;朱培秋;姜薇;: "高通量测序分析口服米诺环素对重度寻常痤疮患者肠道菌群的影响", 中国皮肤性病学杂志, no. 11, 17 October 2018 (2018-10-17) *

Also Published As

Publication number Publication date
CN117106622B (en) 2024-05-10

Similar Documents

Publication Publication Date Title
US20220193157A1 (en) Lactobacillus compositions and methods for prevention and treatment of microbial infection
CN102711778B (en) Method for reducing gastro-intestinal inflammation using bifidobacterium animalis bacteria or a fermented dairy product comprising such bacteria
CN103476273A (en) Bifidobacterium bifidum strains for application in gastrointestinal diseases
Hatanaka et al. Effect of Bacillus subtilis C-3102 on loose stools in healthy volunteers
Flach et al. Probiotic research priorities for the healthy adult population: A review on the health benefits of Lactobacillus rhamnosus GG and Bifidobacterium animalis subspecies lactis BB-12
CN110938572B (en) Probiotic composition for relieving side effects of radiotherapy and chemotherapy of nasopharyngeal carcinoma and preparation method thereof
JP5674741B2 (en) Probiotics used to relieve symptoms associated with digestive disorders
CN113583923B (en) Probiotic composition and application thereof in preparation of medicine for treating constipation and depression
KR20190042575A (en) Use of probiotics in the treatment and / or prevention of atopic dermatitis
Selvamani et al. Efficacy of probiotics-based interventions as therapy for inflammatory bowel disease: a recent update
CN112592871B (en) Lactobacillus casei JYLC-374 and application thereof in product for improving male prostate
CN111602761A (en) Probiotic solid beverage for relieving or treating irritable bowel syndrome
CN114774315B (en) Application of lactobacillus rhamnosus strain LRa05 in preparation of immunity enhancing product and/or eczema relieving product
CN104232537B (en) Lactobacillus crispatus and application thereof
CN116814510B (en) Lactobacillus rhamnosus OPB41 capable of preventing or improving Alzheimer's disease and application thereof
CN117106622B (en) Lactobacillus plantarum and application of composition thereof in preparation of medicines for treating internal hemorrhoids
CN111214524A (en) Application of ginseng fermented product
CN115820498A (en) Lactobacillus plantarum YJ2406 and application thereof
AU2022272332A1 (en) Compositions and methods for treating disease
CN114525233A (en) Application of lactobacillus sake and stachyose composition in preparation of medicine for treating constipation
CN111560335A (en) Bifidobacterium lactis for relieving asthma and application thereof
CN118001305B (en) Application of bifidobacterium longum JBLC-141 in preparation of medicine for improving paraneoplastic thrombocytosis
CN118240716A (en) Bifidobacterium breve and application thereof in relieving diarrhea
CN117004503B (en) Saliva combined lactobacillus MB1 and application thereof in preparation of food and medicine for assisting sleep and regulating intestines and stomach
US20190091270A1 (en) Probiotics for use in relieving symptoms associated with gastrointestinal disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant